Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mi | Notice to attend the annual general meeting in Scibase Holding AB (publ) | 149 | PR Newswire | STOCKHOLM, May 14, 2025 /PRNewswire/ -- Shareholders of SciBase Holding AB (publ), reg. no. 556773-4768 (the "Company"), are hereby summoned to the annual general meeting to be held on 17... ► Artikel lesen | |
Di | SciBase: Interim report | 162 | PR Newswire | STOCKHOLM, May 13, 2025 /PRNewswire/ --
January 1 - March 31, 2025
The first quarter in figures
Net sales were TSEK 8,856 (6,057), +46%. The loss after tax was TSEK 27,510... ► Artikel lesen | |
11.04. | SciBase launches next generation Nevisense | 209 | PR Newswire | STOCKHOLM, April 11, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders, is proud to announce... ► Artikel lesen | |
SCIBASE Aktie jetzt für 0€ handeln | |||||
25.02. | Year-end report: SciBase | 279 | PR Newswire | STOCKHOLM, Feb. 25, 2025 /PRNewswire/ --
January 1 - December 30, 2024
The fourth quarter in figures
Net sales were TSEK 8,598 (5,764), +49%.The loss after tax was TSEK 17... ► Artikel lesen | |
25.02. | SCIBASE: Year-end report | 5 | Cision News | ||
21.02. | SciBase: New study shows significant improved clinical accuracy with Nevisense for both US and German dermatologists | 277 | PR Newswire | STOCKHOLM, Feb. 21, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders announced today, that... ► Artikel lesen | |
30.01. | SciBase continues US expansion, on-boards Several US Dermatology Practices that Specialize in Skin Cancer Detection | 223 | PR Newswire | STOCKHOLM, Jan. 30, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders announced today that... ► Artikel lesen | |
28.01. | SciBase: New review article highlights Nevisense effectiveness in identifying malignant skin lesions | 271 | PR Newswire | STOCKHOLM, Jan. 28, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders announced today that... ► Artikel lesen | |
27.01. | SciBase: Recalculation of warrants of series TO 2 following rights issue | 377 | PR Newswire | STOCKHOLM, Jan. 27, 2025 /PRNewswire/ -- In accordance with the terms and conditions for warrants of series TO 2, which were issued in connection with the capital raise announced in April... ► Artikel lesen | |
23.01. | SciBase: Nevisense (EIS) included in updated German (S1) imaging guidelines | 422 | PR Newswire | STOCKHOLM, Sweden, Jan. 23, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today... ► Artikel lesen | |
23.01. | SCIBASE: Nevisense (EIS) included in updated German (S1) imaging guidelines. | 2 | Cision News | ||
14.01. | SciBase announces final outcome of directed issue and rights issue | 416 | PR Newswire | STOCKHOLM, Jan. 14, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase" or the "Company") today announces the final outcome of the capital raise, consisting of a rights issue of units of approximately... ► Artikel lesen | |
13.01. | SciBase announces outcome of directed issue and preliminary outcome of rights issue | 439 | PR Newswire | STOCKHOLM, Jan. 13, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase" or the "Company") today announces the preliminary outcome of the capital raise, consisting of a rights issue of units... ► Artikel lesen | |
03.01. | SciBase: The Mayo Clinic, the leading US hospital, will test Nevisense in Pilot | 460 | PR Newswire | STOCKHOLM, Jan. 3, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders, announced today that... ► Artikel lesen | |
27.12.24 | Today the subscription period in SciBase rights issue begins | 615 | PR Newswire | STOCKHOLM, Dec. 27, 2024 /PRNewswire/ -- Today, on December 27, 2024, is the first day of the subscription period in SciBase Holding AB's ("SciBase" or the "Company") rights issue of units... ► Artikel lesen | |
20.12.24 | SciBase letter from the CEO | 500 | PR Newswire | STOCKHOLM, Dec. 20, 2024 /PRNewswire/ -- In 2024, SciBase has advanced its positions significantly and laid the foundation for continued growth, with a new organization in the US, success... ► Artikel lesen | |
20.12.24 | SciBase publishes prospectus | 514 | PR Newswire | STOCKHOLM, Dec. 20, 2024 /PRNewswire/ -- SciBase Holding AB ("SciBase" or the "Company") announced on November 12, 2024 that the Board of Directors has resolved, subject to the subsequent... ► Artikel lesen | |
18.12.24 | XFRA CAPITAL ADJUSTMENT INFORMATION - 18.12.2024 | 406 | Xetra Newsboard | Das Instrument 087 GB00BD7XPJ64 NEWRIVER REIT LS-,01 EQUITY wird cum Kapitalmassnahme gehandelt am 18.12.2024 und ex Kapitalmassnahme am 19.12.2024 The instrument 087 GB00BD7XPJ64 NEWRIVER REIT LS-... ► Artikel lesen | |
13.12.24 | Bulletin from the extraordinary general meeting in SciBase Holding AB (publ) | 449 | PR Newswire | STOCKHOLM, Dec. 13, 2024 /PRNewswire/ -- Today, an extraordinary general meeting has been held in SciBase Holding AB (publ) ("SciBase" or the "Company"). The general meeting resolved in accordance... ► Artikel lesen | |
13.11.24 | SciBase Announces Positive Findings in Case Study Monitoring Treatment Outcomes in Atopic Dermatitis Patient | 453 | PR Newswire | STOCKHOLM, Nov. 13, 2024 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of artificial intelligence (AI)-based solutions for skin is excited to announce the... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
ROKU | 63,08 | -1,97 % | It's Possible to Set Up a VPN on Roku, But You'll Need to Follow These Steps | ||
SERNOVA BIOTHERAPEUTICS | 0,133 | -2,21 % | Sernova Biotherapeutics Inc: Sernova talks interim data from Cell Pouch trial | ||
BOSTON SCIENTIFIC | 91,40 | -0,87 % | Is it Worth Retaining Boston Scientific Stock in Your Portfolio Now? | ||
PAUL HARTMANN | 253,00 | +0,80 % | Dividendenbekanntmachungen (02.05.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ADECOAGRO SA LU0584671464 0,175 USD 0,155 EUR AKER ASA NO0010234552 26,5 NOK 2,2495 EUR ALIMAK GROUP AB SE0007158910 3 SEK 0... ► Artikel lesen | |
SYSMEX | 15,500 | -1,90 % | Macrium Software: Macrium Partners with Sysmex America to Reduce Medical Testing Downtime and Improve Patient Care | British-based backup and recovery technology reduces labour costs by up to 75% while minimising downtime, creating a win-win for healthcare providers and patients.
MANCHESTER, England... ► Artikel lesen | |
ADDLIFE | 17,020 | -0,53 % | Dividendenbekanntmachungen (09.05.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AAK AB SE0011337708 5 SEK 0,4573 EUR ADDLIFE AB SE0014401378 0,75 SEK 0,0686 EUR ALLIANZ SE DE0008404005 - 15,4 EUR ALZCHEM GROUP... ► Artikel lesen | |
EMBECTA | 10,400 | 0,00 % | Embecta Corp. Reports Second Quarter Fiscal 2025 Financial Results | PARSIPPANY, N.J., May 09, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta" or the "Company") (Nasdaq: EMBC), a global diabetes care company, today reported financial results for the three and six... ► Artikel lesen | |
R1 RCM | 13,400 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 19.11.2024 | The following instruments on Boerse Frankfurt do have their last trading day on 19.11.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 19.11.2024ISIN NameAU000000SVW5 SEVEN... ► Artikel lesen | |
ENOVIS | 32,400 | -0,61 % | Enovis Corporation: Enovis Announces First Quarter 2025 Results | Continued commercial momentum with first-quarter sales growth of 8% on a reported basis and strong adjusted EBITDA margin expansion First-quarter Reconstructive sales grew 11% year-over-year on a reported... ► Artikel lesen | |
KANGJI MEDICAL | 0,835 | +1,21 % | KANGJI MEDICAL (09997): TERMINATION OF DISCLOSEABLE TRANSACTION IN RELATION TO THE DISPOSAL OF A SUBSIDIARY AND LAND RESUMPTION AGREEMENT WITH GOVERNMENT ... | ||
PULMONX | 2,840 | -4,05 % | Pulmonx Corporation: Pulmonx Reports Record Fourth Quarter and Full Year 2024 Financial Results | REDWOOD CITY, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported... ► Artikel lesen | |
SI-BONE | 17,000 | +1,19 % | SI-BONE, Inc. Reports Financial Results for the First Quarter 2025 and Updates 2025 Guidance | First Quarter 2025 Financial Highlights (all comparisons are to the prior year period) Worldwide revenue of $47.3 million, representing growth of 24.9%U.S. revenue of $44.8 million, representing... ► Artikel lesen | |
REVITALIST LIFESTYLE AND WELLNESS | 0,015 | -100,00 % | Revitalist Lifestyle & Wellness Ltd: Revitalist Announces Filing of Audited Financial Statements for the Year-Ended December 31, 2022 and Provides Update on Cease Trade Order | Vancouver, British Columbia--(Newsfile Corp. - February 18, 2025) - Revitalist Lifestyle and Wellness Ltd. (CSE: CALM) (OTCQB: RVLWF) (FSE: 4DO) (the "Company") wishes to announce that, further to... ► Artikel lesen | |
KOOTH | 1,600 | -0,62 % | Kooth PLC - Annual Financial Report | ||
PEIJIA MEDICAL | 0,595 | -3,25 % | PEIJIA-B (09996): GRANT OF SHARE OPTIONS |